Authors : Somchai Amornyotin
Volume : 49
Issue : 6
Year : 2023
Page No : 375-380
Remimazolam (CNS 7056) is a new rapidly metabolized benzodiazepine and has been presented in clinical research protocols. It is water-soluble and when diluted into a solution becomes a painless injectate. Remimazolam is most soluble in slightly acidic environments and can precipitate in lactated or acetated Ringer’s solution. It has promising characteristics as a sedative drug in clinical anesthesia because of its rapid onset of action, ultrashort duration, and fast recovery time. Midazolam is the parent compound of remimazolam; therefore, remimazolam has a gamma-aminobutyric acid (GABA) neurotransmitter receptor mechanism of action. Remimazolam is rapidly metabolized by nonspecific esterases, mainly localized in the human liver. After administration, plasma concentrations of remimazolam certainly and rapidly decrease, and with adequate dosing, there is no prolonged sedative effect.